Evidence map›Paper›PMID 26909224›Full record

ArticleWorld journal of gastrointestinal pathophysiology2016

Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.

Marcello Cintolo, Giuseppe Costantino, Socrate Pallio, Walter Fries

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal pathophysiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Biomedical optics express · 2017
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marcello CintoloMarcello Cintolo, Giuseppe Costantino, Walter Fries, Clinical Unit for Chronic Bowel Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Giuseppe CostantinoMarcello Cintolo, Giuseppe Costantino, Walter Fries, Clinical Unit for Chronic Bowel Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Socrate PallioMarcello Cintolo, Giuseppe Costantino, Walter Fries, Clinical Unit for Chronic Bowel Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Walter FriesMarcello Cintolo, Giuseppe Costantino, Walter Fries, Clinical Unit for Chronic Bowel Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past decade, thanks to the introduction of biologic therapies, a new therapeutic goal, mucosal healing (MH), has been introduced. MH is the expression of an arrest of disease progression, resulting in minor hospitalizations, surgeries, and prolonged clinical remission. MH may be achieved with several therapeutic strategies reaching success rates up to 80% for both, ulcerative colitis (UC) and Crohn's disease (CD). Various scoring systems for UC and for the transmural CD, have been proposed to standardize the definition of MH. Several attempts have been undertaken to de-escalate therapy once MH is achieved, thus, reducing the risk of adverse events. In this review, we analysed the available studies regarding the achievement of MH and the subsequent treatment de-escalation according to disease type and administered therapy, together with non-invasive markers proposed as predictors for relapse. The available data are not encouraging since de-escalation after the achievement of MH is followed by a high number of clinical relapses reaching up to 50% within one year. Unclear is also another question, in case of combination therapies, which drug is more appropriate to stop, in order to guarantee a durable remission. Predictors of unfavourable outcome such as disease extension, perianal disease, or early onset disease appear to be inadequate to foresee behaviour of disease. Further studies are warranted to investigate the role of histologic healing for the further course of disease.

Indexed as

Biological therapyCrohn’s diseaseDeep remissionDe-escalationDiscontinuationImmunosuppressorsMucosal healingUlcerative colitis

Identifiers

PMID26909224
PMCPMC4753175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.